 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
1 July 1995 | Volume 123 Issue 1 | Pages 18-26
Objective: To determine whether preemptive ganciclovir therapy administered daily during antilymphocyte antibody therapy can prevent cytomegalovirus disease in renal transplant recipients who are positive for cytomegalovirus antibody.
Design: Randomized, controlled, multicenter trial.
Setting: 6 university-affiliated transplantation centers.
Patients: 113 renal transplant recipients who were positive for cytomegalovirus antibody.
Intervention: Patients were randomly assigned to receive either 1) ganciclovir, 2.5 mg/kg body weight administered intravenously on every day that antilymphocyte antibody therapy was administered or 2) no anticytomegalovirus therapy.
Measurements: Patients were observed for 6 months after completion of antilymphocyte antibody therapy for development of cytomegalovirus disease and cytomegalovirus viremia.
Results: Cytomegalovirus disease occurred in 14% of patients (9 of 64) who received preemptive ganciclovir therapy and in 33% of controls (16 of 49) (P = 0.018). Cytomegalovirus was isolated from buffy-coat specimens from 17% of patients (11 of 64) receiving preemptive ganciclovir and from 35% of controls (17 of 49) (P = 0.03). Controlling for the reason (induction or treatment of rejection) for using antilymphocyte antibodies in a Cox proportional-hazards model, we found that preemptive ganciclovir still protected against cytomegalovirus disease (adjusted relative risk, 0.27; 95% CI, 0.12 to 0.64). No adverse events were attributed to preemptive ganciclovir therapy during or within 6 months of its administration.
Conclusions: Preemptive ganciclovir therapy administered daily during courses of treatment with antilymphocyte antibodies reduced the excessive occurrence of cytomegalovirus disease in renal transplant recipients who were positive for cytomegalovirus antibody. This approach, which links the most potent immunosuppression to intensive antimicrobial therapy, allows preventive therapy to be given to those patients at greatest risk for developing infectious complications. These patients are likely to benefit most from the preventive strategy.
*For a listing of the members of the Task Force on Principles for Economic Analysis, see Appendix B.
Author and Article Information
From Massachusetts General Hospital and New England Medical Center, Boston, Massachusetts. Yale University School of Medicine, New Haven, Connecticut. Albany Medical College, Albany, New York. Northwestern Memorial Hospital and University of Chicago Medical Center, Chicago, Illinois. Emory University Medical School, Atlanta, Georgia.
ARTICLE
Preemptive Ganciclovir Therapy To Prevent Cytomegalovirus Disease in Cytomegalovirus Antibody-Positive Renal Transplant Recipients
A Randomized Controlled Trial
For author affiliations and current author addresses, see end of text.
Requests for Reprints: Patricia L. Hibberd, MD, PhD, Infectious Disease Unit, Massachusetts General Hospital, Fruit Street, GRJ-504, Boston, MA 02114.
Acknowledgments: The authors thank Maureen Doran, RN, MPH, and Angela DelVecchio, RN, for collecting the data from the six study sites, ensuring its completeness and accuracy, and doing the data entry. The authors also thank Drs. A. Benedict Cosimi and Nesli O. Basgoz for their assistance with this study.
Grant Support: In part by a grant from Ortho Pharmaceutical Corporation. Ganciclovir was provided by Syntex Laboratories, Inc.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  B. H. Tan CMV prophylaxis--to do or not to do, that is the question Nephrol. Dial. Transplant., July 1, 2006; 21(7): 1757 - 1761. [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Kalil and J. Stoner Strategies To Prevent Organ Disease by Cytomegalovirus in Solid Organ Transplant Recipients Ann Intern Med, March 21, 2006; 144(6): 457 - 457. [Full Text] [PDF]
|
|
|
|
|
|
S. Dummer Controlling the Troll Ann Intern Med, March 21, 2006; 144(6): 458 - 458. [Full Text] [PDF]
|
|
|
|
|
|
N. Singh and M. M. Wagener Strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med, March 21, 2006; 144(6): 456 - 457. [Full Text] [PDF]
|
|
|
|
|
|
A. C. Kalil, E. Lyden, and J. Stoner Controlling the troll. Ann Intern Med, March 21, 2006; 144(6): 457 - 458. [Full Text] [PDF]
|
|
|
|
|
|
A. C. Kalil, J. Levitsky, E. Lyden, J. Stoner, and A. G. Freifeld Meta-Analysis: The Efficacy of Strategies To Prevent Organ Disease by Cytomegalovirus in Solid Organ Transplant Recipients Ann Intern Med, December 20, 2005; 143(12): 870 - 880. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Vaessen, N. Kamar, M. Mehrenberger, C. Mazerolles, C. Mengelle, P. Rischmann, L. Rostaing, and B. Malavaud Severe cytomegalovirus ureteritis in a renal allograft recipient with negative CMV monitoring Nephrol. Dial. Transplant., January 1, 2005; 20(1): 227 - 230. [Full Text] [PDF]
|
|
|
|
 |
|
 J.-Y. Wang, Y.-L. Chang, L.-N. Lee, J.-H. Chen, J.-L. Tang, P.-C. Yang, and Y.-C. Lee Diffuse pulmonary infiltrates after bone marrow transplantation: the role of open lung biopsy Ann. Thorac. Surg., July 1, 2004; 78(1): 267 - 272. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Anglicheau, A. Lautrette, C. Scieux, M. Flamant, F. Morinet, and C. Legendre Efficacy and safety of lowering immunosuppression to treat CMV infection in renal transplant recipients on valaciclovir prophylaxis: a pilot study Nephrol. Dial. Transplant., August 1, 2003; 18(8): 1654 - 1656. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Anglicheau, A. Lautrette, C. Scieux, M. Flamant, F. Morinet, and C. Legendre Efficacy and safety of lowering immunosuppression to treat CMV infection in renal transplant recipients on valaciclovir prophylaxis: a pilot study Nephrol. Dial. Transplant., August 1, 2003; 18(88): 1654 - 1656. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. C. BRENNAN Cytomegalovirus in Renal Transplantation J. Am. Soc. Nephrol., April 1, 2001; 12(4): 848 - 855. [Full Text] [PDF]
|
|
|
|
|
|
M. J. Leikis, A. J. B. Denford, G. B. Pidgeon, and P. J. Hatfield Post-renal transplant obstruction caused by cytomegalovirus ureteritis Nephrol. Dial. Transplant., December 1, 2000; 15(12): 2063 - 2064. [Full Text] [PDF]
|
|
|
|
 |
|
 Management of herpes virus infections following transplantation J. Antimicrob. Chemother., June 1, 2000; 45(6): 729 - 748. [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Caliendo, K. St. George, S.-Y. Kao, J. Allega, B.-H. Tan, R. LaFontaine, L. Bui, and C. R. Rinaldo Comparison of Quantitative Cytomegalovirus (CMV) PCR in Plasma and CMV Antigenemia Assay: Clinical Utility of the Prototype AMPLICOR CMV MONITOR Test in Transplant Recipients J. Clin. Microbiol., June 1, 2000; 38(6): 2122 - 2127. [Abstract] [Full Text]
|
|
|
|
 |
|
 I. G. Sia and R. Patel New Strategies for Prevention and Therapy of Cytomegalovirus Infection and Disease in Solid-Organ Transplant Recipients Clin. Microbiol. Rev., January 1, 2000; 13(1): 83 - 121. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Fishman and R. H. Rubin Infection in Organ-Transplant Recipients N. Engl. J. Med., June 11, 1998; 338(24): 1741 - 1751. [Full Text] [PDF]
|
|
|
|
|
|
C. S. Crumpacker Ganciclovir N. Engl. J. Med., September 5, 1996; 335(10): 721 - 729. [Full Text] [PDF]
|
|
|
|
|
|
T. C. Merigan A Quarter-Century of Antiviral Therapy N. Engl. J. Med., December 21, 1995; 333(25): 1704 - 1705. [Full Text]
|
|
|
|
 |
|
 GANCICLOVIR PREVENTS CMV IN RENAL TRANSPLANT RECIPIENTS Journal Watch (General), July 11, 1995; 1995(711): 6 - 6. [Full Text]
|
|
Article
